In plain terms

The claim being assessed: Low circulating 25-hydroxyvitamin D is a causal contributor to non-skeletal disease, such that supplementation reduces incidence.

Where the evidence stands: Γ — Plausible mechanism. There is a believable biological story and partial support, but the causal step has not been demonstrated.

What this mechanism does: The evidence reviewed does not show this mechanism causing the outcome. That does not show it has no effect.

Strongest evidence for it: Overall Γ is a partial-mechanism assessment for the registered broad prevention claim, not a denial of vitamin-D biology or skeletal indications. Robust null trials and attenuated secondary evidence prevent a broad positive causal crossing; genetic and disease-specific findings keep this above a purely associational interpretation.

What decisive evidence would look like

In plain terms, researchers would change the proposed cause, confirm it changed as intended, and measure a meaningful health outcome while checking other explanations. The result should be able to support or count against the claim.

Relative explanatory fit: Alternative ranked ahead

What this review means

Broad nonskeletal disease prevention by vitamin-D correction is not established; narrower deficiency and disease-specific questions remain open.

Implications for health and treatment: Overall Γ is a partial-mechanism assessment for the registered broad prevention claim, not a denial of vitamin-D biology or skeletal indications. Robust null trials and attenuated secondary evidence prevent a broad positive causal crossing; genetic and disease-specific findings keep this above a purely associational interpretation.

Limits for individual care: 50 primary reports with 3 selected partial-body examinations; density, heterogeneous controls and incomplete access set the confidence, not correctness. The grade applies to the exact registered claim; stronger findings for narrower subclaims remain separate. No complete-paper audit or blinded calibration is claimed. This educational review does not establish an individual treatment recommendation.

Medical information notice: This review provides general health information, not medical advice. It cannot diagnose a condition or replace an individual discussion with a qualified clinician.

Source checking used bounded original primary abstract passages/status records and selected original partial-body passages. No complete-abstract or complete-paper audit, or independent scientific peer review, is claimed. Detailed access counts and limitations appear in the review.

A low grade is not an accusation. It means the causal work has not been done yet, which is the ordinary state of most actively studied mechanisms in biology.

At a glance

Sub-claims assessed separately

Figures

Explanatory figures summarizing this review. They carry no evidential weight of their own; where a figure and the review differ, the review governs.

Full assessment

From here the review is written for a technical reader: caps and thresholds, competing models, the independence basis, and the citation ledger.

Sources: 50 primary reports; claims: 54; verified: 54; unverified: 0. Verification is bounded attribution. Access: 3 partial-body and 47 bounded abstract/status examinations. Literature cutoff: 2026-10-09; source examination UTC date: 2026-10-10. No complete-paper audit or blinded calibration claimed.

Adversarial review: Generated by Sol 6.1; adversarially reviewed by Claude Opus 5.5 (Anthropic) on 2026-10-14. 4 corrections applied (see ADVERSARIAL REVIEW AND APPROVAL). Status: Approved as revised.

AT A GLANCE

Broad nonskeletal disease prevention by vitamin-D correction is not established; narrower deficiency and disease-specific questions remain open.

Deciding experiment: Randomize correction within prespecified, safely enrolled baseline-deficiency strata, using registered disease-specific incidence endpoints and measured biochemical engagement; compare across strata without conditioning on achieved levels.

Belief versus evidence: Overall Γ is a partial-mechanism assessment for the registered broad prevention claim, not a denial of vitamin-D biology or skeletal indications. Robust null trials and attenuated secondary evidence prevent a broad positive causal crossing; genetic and disease-specific findings keep this above a purely associational interpretation.

Best-supported rival: Risk marker with selective causal effects. Prespecified baseline deficiency and disease category, verified correction and randomized incidence endpoints separate a causal deficiency effect from shared-cause associations; defining responders afterward cannot supply the scope.

COMPETING MECHANISTIC MODELS

Rank 1: Risk marker with selective causal effects (Γ). Low vitamin D is often a marker of shared causes, with possible disease- and deficiency-specific causal contributions. Broad trial nulls coexist with selected genetic and clinical signals. This mixed explanation does not resolve the size of every severe-deficiency effect.

Rank 2: Broad deficiency-driven nonskeletal disease (Γ). Low vitamin D is an upstream common cause whose correction prevents multiple disease categories. Observational gradients, immune biology and original autoimmune-trial findings support a plausible rationale. Large cancer, cardiovascular, respiratory and other trials do not provide consistent broad incidence benefit.

Rank 3: Predominantly reverse causation/confounding (Β). Illness, adiposity, sun exposure and behavior influence both vitamin-D levels and risk. Associations are often stronger than randomized correction effects. Selected genetic and clinical findings prevent concluding all effects are noncausal.

Rank 4: Baseline-dependent immune modulation (Γ). Effects may be concentrated in prespecified deficient or disease-specific strata. Selected low-baseline and psoriasis genetic findings support testing this possibility. Postrandomization achieved levels and unreplicated subgroup signals do not establish the boundary.

The tournament does not alter the nominal level. Compatible pathways and flexible alternatives are not automatically proved by explaining observations.

FULL REVIEW

Registered claim and scope

Low circulating 25-hydroxyvitamin D is a causal contributor to non-skeletal disease, such that supplementation reduces incidence.

The website claim hinges on SC3 at its stated scope; SC1 and SC2 are reported separately and cannot substitute for that claim.

Selection: remaining-priority list position 3 from the editorial list of 2026-10-09. No prior grade consulted; this is not independent blinded calibration.

Evidence and causal interpretation

Rubric fit: 06-metabolism-aging is a partial fit for broad healthspan inference; 05-immunology-inflammation covers immune subclaims. Aging/lifespan requirements are not used to deny disease-specific prevention. The full claim requires causal incidence changes across its stated nonskeletal scope, not vitamin-D concentration or immune biomarkers alone.

Vitamin D is biologically active, and low levels can predict illness without proving that correcting them prevents it. Genetic studies suggest selective rather than universal causal effects, and instrument/nonlinear-stratification assumptions require explicit caution. The present grade applies to broad nonskeletal prevention, leaving skeletal physiology outside the graded claim. [33] [42] [49] [48]

VITAL did not reduce its primary cancer or major cardiovascular endpoints. D-Health adds null overall cancer and mortality results; its cardiovascular analysis is suggestive rather than a definitive broad effect. Depression, cognition, frailty and respiratory findings do not form a convergent positive prevention case. These secondary reports share parent trial participants. [1] [10] [12] [6] [2] [7] [3]

The strongest original autoimmune result needs its update. After newly confirmed cases with randomized-period onset were incorporated, the vitamin-D hazard ratio was 0.85 with confidence interval 0.70–1.04, replacing the original significant estimate for this inference. Subsequent off-treatment observation is not continued randomized exposure. [24] [25]

D2d did not meet its primary diabetes-prevention threshold, while selected subgroup/genotype signals remain testable. Associations with achieved concentrations condition on a postrandomization variable. The Mongolian child trial raised vitamin-D levels in a largely deficient population without preventing tuberculosis infection/disease, so replete recruitment cannot explain every null. Treatment symptom resolution in tuberculosis is a different claim. [16] [17] [19] [21] [39] [36]

HYPOTHESIS STATE EVALUATION FRAMEWORK (HSEF v5.3)

Consensus consistency validation — 9 October 2026

Cutoff: 2026-10-09. Provider artifacts: consensus-browser-response.md (verbatim, citation markers preserved), browser-thread.json, consensus-search-raw.json. Consensus thread: Vitamin D causality and chronic diseases, Pro. The response is a useful discovery map, but most bibliography entries are reviews, guidelines, or meta-analyses; their summaries are not treated as primary verification. The hypothesized exposure is deficiency, whereas most large RCTs test supplementation in broad populations with modest baseline deficiency; these are not interchangeable estimands.

Primary-source reconciliation

• PMID 30415629; DOI 10.1056/NEJMoa1809944 (VITAL primary RCT). 25,871 generally healthy older adults randomized to 2,000 IU/day vitamin D3 or placebo; over 5.3 years no significant reduction in invasive cancer (HR 0.96, 95% CI 0.88–1.06), major CVD (HR 0.97, 0.85–1.12), or all-cause mortality (HR 0.99, 0.87–1.12); cancer-mortality signal was uncertain. Original package evidence source 1, full-text-partial, study key VITAL; already counted.
• PMID 37380191; DOI 10.1136/bmj-2023-075230 (D-Health primary RCT secondary endpoint analysis). 21,315 adults aged 60–84 randomized to 60,000 IU/month or placebo for up to 5 years. Composite major CV event HR 0.91 (0.81–1.01), absolute difference CI spans zero; MI HR 0.81 (0.67–0.98), stroke null. Subgroup interaction among those using CV drugs was not significant. Original evidence ledger source 6 in selected-records.json, evidence.json, canonical review, and appraisals.tsv; study key D_HEALTH. It was already counted. The endpoint paper belongs to the same D_HEALTH randomized cohort and is not an independent trial.
• PMID 35026158; DOI 10.1016/S2213-8587(21)00345-4 (D-Health primary mortality report). Original ledger source 12, study key D_HEALTH, already counted. RCT population-level mortality outcome showed no clear mortality reduction; it shares randomization/cohort with the above D-Health reports and must not be counted as an independent trial.
• PMID 40096917; DOI 10.1016/j.jsbmb.2025.106738 (D-Health cancer-incidence report). Original ledger source 10, study key D_HEALTH, already counted; this is another outcome report from the same randomized cohort, not a new RCT. It informs the null/qualified pattern but does not independently multiply evidence.

Claim/score judgement

The review’s core distinction remains sound: observational deficiency associations do not by themselves demonstrate supplementation causality, and the large trials are not direct tests of treating frank deficiency. Broad disease-prevention claim overall remains Γ / Moderate; no score change. VITAL’s population and endpoints, D-Health’s modest/uncertain composite and subgroup interaction, and shared trial groups preserve the same scope limits. No new independent primary trial was established by the Consensus bibliography; its reviews do not add causal units. Original totals remain 50 reports, 54 verified claims. The trial protocol and additional endpoint publications are not new independent trial units. No grade/scorecard patch proposed.

This is a source-anchor reconciliation, not an independent blinded review. Consensus summaries/tags were not treated as primary findings or tiers.

Primary record links

PMID 30415629 · PMID 37380191 · PMID 35026158 · PMID 40096917

This dated supplement adds source reconciliation to the original review. Its original narrative, registered scope, source inventory and grades remain historical records. No earlier adversarial approval is attached to this case, and nothing in the record certifies this supplement. New sources described here are supplemental and are not counted in the original inventory.

Subclaim matrix and aggregation

Preregistered aggregation: primary-subclaim. Overall Γ is a partial-mechanism assessment for the registered broad prevention claim, not a denial of vitamin-D biology or skeletal indications. Robust null trials and attenuated secondary evidence prevent a broad positive causal crossing; genetic and disease-specific findings keep this above a purely associational interpretation. Sensitivities: weakest-link Β; primary-subclaim Γ; scope-matched Γ.

Decisive-perturbation inventory and causal tally

[1] VITAL did not significantly reduce its primary invasive-cancer or major-cardiovascular endpoints with vitamin D. This constrains broad prevention in the enrolled population, not every severely deficient or disease-specific subgroup.

[2] VITAL-DEP did not significantly prevent depression outcomes. This is not a trial of treating every existing depressive disorder or severe deficiency.

[3] VITAL frailty analyses found no clear preventive benefit. Frailty analysis does not establish all possible skeletal or functional effects.

[6] D-Health cardiovascular analyses suggested a modest signal with an overall confidence interval including no effect. Nominal secondary/subgroup findings are not definitive broad cardiovascular prevention.

[7] D-Health cognitive analyses found no benefit on tested cognition. Same parent trial, selected measures and enrollment restrict scope.

[9] D-Health tertiary analyses did not reduce incident hypothyroidism. A tertiary endpoint is not independent confirmation of autoimmune prevention.

[10] D-Health did not reduce overall cancer incidence. Not all cancer subtypes or severely deficient populations are separately resolved.

[12] D-Health did not reduce all-cause mortality. Exploratory cancer-mortality analyses do not establish generalized harm; an erratum is attached.

[13] D-Health did not reduce acute respiratory infection incidence, with limited duration findings. Episode duration is distinct from prevention incidence and from severe-deficiency effects.

[15] D-Health did not change the tested telomere-length endpoint. Telomere length is not a validated substitute for organismal aging or disease prevention.

[16] D2d's primary diabetes endpoint favored supplementation numerically but did not reach statistical significance. Participants were not selected for vitamin-D deficiency; the result does not prove benefit or exclude a modest effect.

[24] The original VITAL autoimmune report found a statistically significant reduction in confirmed incident autoimmune disease. The same cohort's later case confirmation attenuated the estimate; it is not an independently replicated broad signal.

[25] Updated VITAL cases weakened the randomized vitamin-D autoimmune estimate and follow-up showed no overall sustained vitamin-D difference. Observational post-trial follow-up is not continued randomized supplementation; attenuation does not exclude all disease-specific effects.

[34] Supplementation increased a T-regulatory-cell measure in a controlled study. Immune-cell percentage change did not demonstrate beta-cell function or disease-incidence benefit.

[36] Adjunct vitamin D improved selected symptom-resolution outcomes in children treated for tuberculosis. Treatment response is not prevention of tuberculosis infection or broad disease incidence.

[39] Supplementation raised vitamin-D levels but did not prevent tuberculosis infection or disease in a largely deficient child population. Specific population and outcome; null disease incidence is not proof of every vitamin-D mechanism's absence.

[40] VITAL found no overall reduction in upper-respiratory infection. The very-low-baseline subgroup was small and uncertain, so not all severe-deficiency effects are resolved.

[50] ViDA did not reduce cardiovascular events with its tested supplementation regimen. Regimen and population context matter; no inference to all possible dosing or severe deficiency.

Tally: 18 discriminating contrasts. Null and negative contrasts are discriminators, not positive threshold crossings. Reports and replications are not independent causal lines. The tally counts reports with discriminating intervention contrasts, including negative results; it is not a count of positive causal crossings. Shared parent trials and multiple manipulations within a study remain grouped.

Cap audit, precedence and Β/Γ/Δ boundary

Biochemical correction confirms exposure but does not itself cross a clinical prevention threshold. Positive immune-pathway or disease-specific results retain their scopes; null broad prevention does not negate skeletal biology. The nominal Γ is an unmet causal threshold assessment, not a claim that all trials or all mechanisms are biomarker-only.

Universal six-cap audit: 1: In vitro evidence alone cannot exceed Γ; cell and biochemical findings do not establish human endogenous causality. 2: Pure association evidence cannot exceed Β; association-only presence/risk/reliability subclaims retain Β. 3: Overexpression in model systems caps at Γ for the broader claim; artificially engaged targets are not endogenous human necessity. 4: Biomarker change without functional/phenotypic change caps at Γ; clocks, concentrations and immune markers cannot replace functional outcomes. 5: Seeding or forced-transfer paradigms cap at Γ for endogenous propagation claims; injected spike, transferred IgG and forced model stimulation retain their model scope. 6: Familial/syndromic genetic findings remain scope-restricted; ALS/syndromic model mechanisms do not automatically establish general aging or sporadic human disease. None of these is reapplied to downgrade a genuinely convergent same-scope causal set.

Gamma hard-rule audit: Human associations and biomarker-only changes do not establish the broad causal claim. Model perturbations bind their tested species and phenotype, not an untested human scope. Positive treatment effects are checked for specific mechanism attribution; negative trials require target engagement before mechanistic falsification.

SC1 cap: “Pure association evidence — however large, however replicated — cannot exceed Β.” Low vitamin D predicts selected disease risks but illness, adiposity, exposure and behavior can confound those associations.

SC1 field-valid definition: “ - Genetic or pharmacologic intervention producing reproducible lifespan/healthspan extension - Must separate developmental effects from true aging effects - Biomarker change alone does NOT satisfy this threshold” Positive full-scope result: no. Low vitamin D predicts selected disease risks but illness, adiposity, exposure and behavior can confound those associations.

SC2 field-valid definition: “ - Cell-type-specific conditional knockout or depletion - Pathway-specific blockade (not broad immunosuppression) changing disease course - Human targeted therapy with mechanistic alignment showing disease-modifying effect” Positive full-scope result: no. Biological signaling, immune-cell changes and selected genetic/disease-specific findings support plausibility; broad nonskeletal causal pathways are not established by biomarkers alone.

SC3 field-valid definition: “ - Genetic or pharmacologic intervention producing reproducible lifespan/healthspan extension - Must separate developmental effects from true aging effects - Biomarker change alone does NOT satisfy this threshold” Positive full-scope result: no. Large randomized trials do not show a consistent broad prevention effect. Positive disease-specific or original secondary findings do not establish the registered across-category claim.

Upward threshold ladder

SC1 Δ: “Requires at least one intervention changing lifespan or healthspan in a way consistent with the hypothesis.” Satisfied: no. A valid genetic/natural-experiment or randomized correction must establish outcome causality beyond the association.

SC2 Δ: “Requires pathway- or cell-type-resolved causal perturbation affecting disease or phenotype.” Satisfied: no. Pathway-specific manipulation must affect the relevant disease course, rather than only immune-cell or serum measures.

SC3 Δ: “Requires at least one intervention changing lifespan or healthspan in a way consistent with the hypothesis.” Satisfied: no. Prespecified deficiency-defined randomized correction must reduce the specified clinical incidences with biochemical engagement and appropriate disease-specific controls.

Upper ladder: No convergence establishes the full registered claim. Positive narrower results are retained without re-capping an assembled causal set; their scopes and distinct failure modes are stated separately.

Independence: Different publications, laboratories and agents do not automatically form independent causal lines. No nominal Ζ or higher is assigned.

Falsification and pitfalls

Superseded estimate. Later VITAL case confirmation attenuated the originally significant autoimmune estimate; both reports are one trial.

Surrogate substitution. Concentration, T-cell changes and telomere measures are not disease-incidence benefit.

Post-outcome scope. Achieved vitamin-D concentrations cannot retrospectively define a randomized responsive group.

Combination attribution. Saxagliptin, peptide/calcitriol and K2/D3 combinations do not isolate vitamin D.

Adversarial steelman: above, then below

Case for Δ: original VITAL autoimmune prevention, selected genetic findings and deficiency-related subgroup signals supply credible causal leads. However, updated randomized-period case confirmation weakened the autoimmune estimate; tuberculosis treatment response is not prevention, and no coherent across-category incidence crossing is established.

Case for Β: strong associations are frequently confounded and broad prevention trials are null. Experimental signaling and selected genetic/disease-specific evidence still supply partial mechanistic support, so a purely association-only classification discards relevant causal leads.

Retain Γ for the exact broad claim; neither original secondary significance nor broad nulls resolve every disease-specific effect. Do not count VITAL follow-ups as independent replication.

Final score, causal direction and M/S/D

Overall Γ is a partial-mechanism assessment for the registered broad prevention claim, not a denial of vitamin-D biology or skeletal indications. Robust null trials and attenuated secondary evidence prevent a broad positive causal crossing; genetic and disease-specific findings keep this above a purely associational interpretation.

For the registered across-category prevention claim, a general dependency on deficiency is not established. Step 2 records this unresolved general role; it does not assert vitamin D is biologically incidental in every disease or in skeletal physiology.

Momentum: Mechanistic only. D-Health cancer incidence (PMID40096917), updated VITAL autoimmune outcomes (PMID38272846) and D2d genotype analyses (PMID42024385) refine disease-specific boundaries. These are completed reports; no verified named pending broad deficiency-correction result was found.

Stability: Stable. No specific pending result with a verified completion trigger was identified in this bounded search; Stable follows the framework definition, not a forecast of permanent truth.

Divergence: Contested; no single implied-level arithmetic. Artifact for the split: supplement marketing, much of the observational literature and parts of clinical practice frame vitamin-D correction as broadly preventive, implying a high rung, while the field's own large randomized trials are read by trialists as showing no broad prevention effect at all, implying the bottom of the ladder for the registered claim (PMID30415629,35026158,40096917,32706534). These dimensions do not change level or confidence.

PROPOSED DECISIVE EXPERIMENTS

Randomize correction within prespecified, safely enrolled baseline-deficiency strata, using registered disease-specific incidence endpoints and measured biochemical engagement; compare across strata without conditioning on achieved levels.

Readout: Confirmed disease incidence and function, biochemical engagement and treatment adherence. Controls: Baseline definition before outcomes, ethical deficiency treatment rules, adjudication blinded to allocation and multiplicity control. Supporting: Reproducible clinically meaningful prevention in the registered deficiency/disease scope. Falsifying: Verified correction without the prespecified incidence effect at adequate precision and follow-up.

KNOWLEDGE GAPS

Severe deficiency remains incompletely represented for several outcomes.

Disease-specific effect sizes and nonlinear exposure assumptions need independent tests.

Genetic instrument validity and pleiotropy remain assumptions.

Some apparent vitamin-D benefits involve combinations or secondary endpoints.

REVIEWER NOTES

Fifty to seventy original primary reports were selected before adjudication. Exact bounded abstract passages and selected body paragraphs are retained with examination receipts. Most papers were not read in full; absent details are limitations, not assumed controls. For the original 2026-10-09 review pass, no independent blind grading, Consensus, Scite or independent scientific peer review was performed. The dated Consensus consistency validation above is a later, separately scoped supplement: it records the Consensus Pro thread used as a discovery map and the original-source reconciliation made on 9 October 2026, changed no grade or source total, and is not an independent blinded review either. Popularity is editorial interest, not measured demand. Models are a descriptive tournament; their rankings are not independent causal proof. Grades were derived from selected primary evidence after claim registration, without consulting a previous completed grade. The primary-subclaim aggregation is fixed; weakest-link sensitivities remain displayed.

Search leads, reviews, protocols and correction notices do not pad the primary count. Downloaded XML does not earn examination credit. Linked notices remain attached; unexamined correction details limit inference. This is a coordinator source/claim consistency assessment, not independent blinded calibration.

ADVERSARIAL REVIEW AND APPROVAL

Authoring model: Sol 6.1. Adversarial reviewer: Claude Opus 5.5 (Anthropic). Date: 2026-10-14 (Round 2, group 12). Scope of checks: 50/50 reference PMIDs verified against PubMed metadata (0 failed, 0 retractions or expressions of concern); 12 load-bearing claims spot-checked against abstracts or the review's declared partial-body receipts, with the four source-level entries added by the 9 October revision checked line by line; scoring logic re-derived against hsef-framework.md and the v5.3 SKILL (rubric routing, pre-registered primary-subclaim aggregation, role derivation, upward ladder, M/S/D artifacts); the known upstream defects screened.

Rejected findings (checked, no change)

1. Level and aggregation. Primary-subclaim is pre-registered and applied as written: SC3 is the designated primary subclaim, it carries the website claim at its stated scope, and its Γ sets the headline while SC1 (Β) and SC2 (Γ) are reported without gating. All three alternatives are reported (weakest-link Β, primary-subclaim Γ, scope-matched Γ). Δ rejected: no randomized trial delivers a positive across-category incidence effect, and the one previously significant autoimmune estimate is explicitly superseded by the updated randomized-period confirmation. Β rejected, which is the harder call in the other direction: selected genetic findings and disease-specific signals keep the claim above pure association, so the review is right not to drop it to a correlational grade merely because the headline trials are null.
2. Confidence band. Moderate retained (see AR-3). The temptation to raise it to High on the strength of two very large independent trials was weighed and declined, because those trials are indirect for the registered deficiency estimand.
3. Momentum. Already "Mechanistic only" and exemplary: the artifact names the work and then says in terms that "These are completed reports; no verified named pending broad deficiency-correction result was found." No change.
4. "Best-supported rival" renderer bug. Checked and absent. The score card marks models_evaluated[0] as is_nominal: false, rank 1 (Risk marker with selective causal effects, Γ); the nominal (Broad deficiency-driven nonskeletal disease, Γ) sits at rank 2.
5. Causal role. epiphenomenon is reached at step 2 of the derivation procedure, and the review correctly records this as an unresolved general role rather than an assertion that vitamin D is biologically incidental; skeletal physiology is explicitly held outside the graded claim.
6. Dated facts and overclaiming. The most dated-fact-sensitive item in this review is handled correctly: the originally significant VITAL autoimmune estimate (HR 0.78, 95% CI 0.61 to 0.99) is not left standing, and the review reports the updated randomized-period estimate of HR 0.85 with a confidence interval of 0.70 to 1.04 after further case confirmation, while refusing to treat the two years of post-intervention observation as continued randomized exposure. The D-Health cancer-incidence null (HR 1.02, 95% CI 0.95 to 1.10), the D-Health cardiovascular composite that crosses no effect, the D2d primary miss, and the Mongolian schoolchildren trial raising levels in a deficient population without preventing tuberculosis infection or disease are all stated accurately and at the right scope.
7. Double counting. Correct and carefully handled: the four D-Health outcome reports and the VITAL secondary analyses are grouped by study key rather than by paper, and the validation block states explicitly that the provider bibliography established no new independent primary trial and that the totals remain 50 reports and 54 verified claims.
8. Citation years. References 1 (2018/2019), 8 (2013/2014) and 46 (2020/2021) differ from the PubMed e-pub year by one. Rejected per convention.
9. Collective-author defect, empty DOI: . fields, "PMIDnot supplied", fused numeral tokens, retrieval artifacts. Screened across all 50 references, the timeline and the evidence cards; none present.

Residual limitations

Only three originals were read at partial-body depth, so several quoted effect estimates (the VITAL cancer and cardiovascular hazard ratios, the D-Health composite and myocardial-infarction estimates, and the updated autoimmune confidence interval) rest on the review's own declared partial-body receipts rather than on text available to this reviewer in full. The raw Consensus browser response named in the validation block was not available here, so its provenance claims were checked only for internal consistency against the review's own statements. Access depth is unchanged (3 partial-body, 47 bounded abstract/status).

Approval: Following adversarial review and the corrections listed above, the revised document is approved. — Claude Opus 5.5 (Anthropic), 2026-10-14.

REFERENCES

1. Manson JE, Cook NR, Lee IM et al. Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease. The New England journal of medicine. 2019. PMID 30415629. DOI: 10.1056/NEJMoa1809944. Access: full_text_partial. Study: VITAL.

2. Okereke OI, Reynolds CF, Mischoulon D et al. Effect of Long-term Vitamin D3 Supplementation vs Placebo on Risk of Depression or Clinically Relevant Depressive Symptoms and on Change in Mood Scores: A Randomized Clinical Trial. JAMA. 2020. PMID 32749491. DOI: 10.1001/jama.2020.10224. Access: abstract_metadata. Study: VITAL.

3. Orkaby AR, Dushkes R, Ward R et al. Effect of Vitamin D3 and Omega-3 Fatty Acid Supplementation on Risk of Frailty: An Ancillary Study of a Randomized Clinical Trial. JAMA network open. 2022. PMID 36098968. DOI: 10.1001/jamanetworkopen.2022.31206. Access: abstract_metadata. Study: VITAL.

4. Vyas CM, Mischoulon D, Chang G et al. Effects of Vitamin D3 and Marine Omega-3 Fatty Acids Supplementation on Indicated and Selective Prevention of Depression in Older Adults: Results From the Clinical Center Sub-Cohort of the VITamin D and OmegA-3 TriaL (VITAL). The Journal of clinical psychiatry. 2023. PMID 37378490. DOI: 10.4088/JCP.22m14629. Access: abstract_metadata. Study: VITAL.

5. Limonte CP, Zelnick LR, Hoofnagle AN et al. Effects of Vitamin D3 Supplementation on Cardiovascular and Cancer Outcomes by eGFR in VITAL. Kidney360. 2022. PMID 36591342. DOI: 10.34067/KID.0006472022. Access: abstract_metadata. Study: VITAL.

6. Thompson B, Waterhouse M, English DR et al. Vitamin D supplementation and major cardiovascular events: D-Health randomised controlled trial. BMJ (Clinical research ed.). 2023. PMID 37380191. DOI: 10.1136/bmj-2023-075230. Access: abstract_metadata. Study: D_HEALTH.

7. Pham H, Waterhouse M, Rahman S et al. Vitamin D supplementation and cognition-Results from analyses of the D-Health trial. Journal of the American Geriatrics Society. 2023. PMID 36715270. DOI: 10.1111/jgs.18247. Access: abstract_metadata. Study: D_HEALTH.

8. Tran B, Armstrong BK, Ebeling PR et al. Effect of vitamin D supplementation on antibiotic use: a randomized controlled trial. The American journal of clinical nutrition. 2014. PMID 24108783. DOI: 10.3945/ajcn.113.063271. Access: abstract_metadata. Study: D_HEALTH_PILOT.

9. Waterhouse M, Pham H, Rahman ST et al. The Effect of Vitamin D Supplementation on Hypothyroidism in the Randomized Controlled D-Health Trial. Thyroid : official journal of the American Thyroid Association. 2023. PMID 37698908. DOI: 10.1089/thy.2023.0317. Access: abstract_metadata. Study: D_HEALTH.

10. Neale RE, English DR, McLeod DS et al. The effect of vitamin D supplementation on cancer incidence in the randomised controlled D-Health Trial: Implications for policy and practice. The Journal of steroid biochemistry and molecular biology. 2025. PMID 40096917. DOI: 10.1016/j.jsbmb.2025.106738. Access: abstract_metadata. Study: D_HEALTH.

11. Tran B, Armstrong BK, Carlin JB et al. Recruitment and results of a pilot trial of vitamin D supplementation in the general population of Australia. The Journal of clinical endocrinology and metabolism. 2012. PMID 23066119. DOI: 10.1210/jc.2012-2682. Access: abstract_metadata. Study: D_HEALTH_PILOT.

12. Neale RE, Baxter C, Romero BD et al. The D-Health Trial: a randomised controlled trial of the effect of vitamin D on mortality. The lancet. Diabetes & endocrinology. 2022. PMID 35026158. DOI: 10.1016/S2213-8587(21)00345-4. Access: abstract_metadata. Study: D_HEALTH.

13. Pham H, Waterhouse M, Baxter C et al. The effect of vitamin D supplementation on acute respiratory tract infection in older Australian adults: an analysis of data from the D-Health Trial. The lancet. Diabetes & endocrinology. 2021. PMID 33444565. DOI: 10.1016/S2213-8587(20)30380-6. Access: abstract_metadata. Study: D_HEALTH.

14. Waterhouse M, Tran B, Ebeling PR et al. Effect of vitamin D supplementation on selected inflammatory biomarkers in older adults: a secondary analysis of data from a randomised, placebo-controlled trial. The British journal of nutrition. 2015. PMID 26206095. DOI: 10.1017/S0007114515002366. Access: abstract_metadata. Study: D_HEALTH_PILOT.

15. Rahman ST, Waterhouse M, Pham H et al. Effects of Vitamin D Supplementation on Telomere Length: An Analysis of Data from the Randomised Controlled D-Health Trial. The journal of nutrition, health & aging. 2023. PMID 37702332. DOI: 10.1007/s12603-023-1948-3. Access: abstract_metadata. Study: D_HEALTH.

16. Pittas AG, Dawson-Hughes B, Sheehan P et al. Vitamin D Supplementation and Prevention of Type 2 Diabetes. The New England journal of medicine. 2019. PMID 31173679. DOI: 10.1056/NEJMoa1900906. Access: abstract_metadata. Study: D2D.

17. Rasouli N, Brodsky IG, Chatterjee R et al. Effects of Vitamin D Supplementation on Insulin Sensitivity and Secretion in Prediabetes. The Journal of clinical endocrinology and metabolism. 2022. PMID 34473295. DOI: 10.1210/clinem/dgab649. Access: abstract_metadata. Study: D2D.

18. Chatterjee R, Fuss P, Vickery EM et al. Vitamin D Supplementation for Prevention of Cancer: The D2d Cancer Outcomes (D2dCA) Ancillary Study. The Journal of clinical endocrinology and metabolism. 2021. PMID 33693713. DOI: 10.1210/clinem/dgab153. Access: abstract_metadata. Study: D2D.

19. Dawson-Hughes B, Huggins GS, Nelson J et al. Vitamin D Receptor Polymorphisms and the Effect of Vitamin D Supplementation on Diabetes Risk Among Adults With Prediabetes. JAMA network open. 2026. PMID 42024385. DOI: 10.1001/jamanetworkopen.2026.7332. Access: abstract_metadata. Study: D2D.

20. Kim SH, Brodsky IG, Chatterjee R et al. Effect of Vitamin D Supplementation on Kidney Function in Adults with Prediabetes: A Secondary Analysis of a Randomized Trial. Clinical journal of the American Society of Nephrology : CJASN. 2021. PMID 34362787. DOI: 10.2215/CJN.00420121. Access: abstract_metadata. Study: D2D.

21. Chatterjee R, Davenport CA, Vickery EM et al. Effect of intratrial mean 25(OH)D concentration on diabetes risk, by race and weight: an ancillary analysis in the D2d study. The American journal of clinical nutrition. 2023. PMID 37001590. DOI: 10.1016/j.ajcnut.2023.03.021. Access: abstract_metadata. Study: D2D.

22. Desouza C, Chatterjee R, Vickery EM et al. The effect of vitamin D supplementation on cardiovascular risk in patients with prediabetes: A secondary analysis of the D2d study. Journal of diabetes and its complications. 2022. PMID 35753926. DOI: 10.1016/j.jdiacomp.2022.108230. Access: abstract_metadata. Study: D2D.

23. Johnson KC, Pittas AG, Margolis KL et al. Safety and tolerability of high-dose daily vitamin D3 supplementation in the vitamin D and type 2 diabetes (D2d) study-a randomized trial in persons with prediabetes. European journal of clinical nutrition. 2022. PMID 35140313. DOI: 10.1038/s41430-022-01068-8. Access: abstract_metadata. Study: D2D.

24. Hahn J, Cook NR, Alexander EK et al. Vitamin D and marine omega 3 fatty acid supplementation and incident autoimmune disease: VITAL randomized controlled trial. BMJ (Clinical research ed.). 2022. PMID 35082139. DOI: 10.1136/bmj-2021-066452. Access: abstract_metadata. Study: VITAL.

25. Costenbader KH, Cook NR, Lee IM et al. Vitamin D and Marine n-3 Fatty Acids for Autoimmune Disease Prevention: Outcomes Two Years After Completion of a Double-Blind, Placebo-Controlled Trial. Arthritis & rheumatology (Hoboken, N.J.). 2024. PMID 38272846. DOI: 10.1002/art.42811. Access: full_text_partial. Study: VITAL.

26. Sonigra A, Nel HJ, Wehr P et al. Randomized phase I trial of antigen-specific tolerizing immunotherapy with peptide/calcitriol liposomes in ACPA+ rheumatoid arthritis. JCI insight. 2022. PMID 36278483. DOI: 10.1172/jci.insight.160964. Access: abstract_metadata. Study: PMID36278483.

27. Stefanić M, Papić S, Suver M et al. Association of vitamin D receptor gene 3'-variants with Hashimoto's thyroiditis in the Croatian population. International journal of immunogenetics. 2008. PMID 18279374. DOI: 10.1111/j.1744-313X.2008.00748.x. Access: abstract_metadata. Study: PMID18279374.

28. Zhang Z, Yan X, Wu C et al. Adding vitamin D3 to the dipeptidyl peptidase-4 inhibitor saxagliptin has the potential to protect β-cell function in LADA patients: A 1-year pilot study. Diabetes/metabolism research and reviews. 2020. PMID 32043288. DOI: 10.1002/dmrr.3298. Access: abstract_metadata. Study: PMID32043288.

29. Koehler VF, Filmann N, Mann WA. Vitamin D Status and Thyroid Autoantibodies in Autoimmune Thyroiditis. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme. 2019. PMID 31766063. DOI: 10.1055/a-1023-4181. Access: abstract_metadata. Study: PMID31766063.

30. Yan X, Li X, Liu B et al. Combination therapy with saxagliptin and vitamin D for the preservation of β-cell function in adult-onset type 1 diabetes: a multi-center, randomized, controlled trial. Signal transduction and targeted therapy. 2023. PMID 37076476. DOI: 10.1038/s41392-023-01369-9. Access: abstract_metadata. Study: NCT02407899.

31. Fang F, Chai Y, Wei H et al. Vitamin D deficiency is associated with thyroid autoimmunity: results from an epidemiological survey in Tianjin, China. Endocrine. 2021. PMID 33759075. DOI: 10.1007/s12020-021-02688-z. Access: abstract_metadata. Study: PMID33759075.

32. Ben-Shabat N, Watad A, Shabat A et al. Low Vitamin D Levels Predict Mortality in Ankylosing Spondylitis Patients: A Nationwide Population-Based Cohort Study. Nutrients. 2020. PMID 32414130. DOI: 10.3390/nu12051400. Access: abstract_metadata. Study: PMID32414130.

33. Zhao SS, Mason A, Gjekmarkaj E et al. Associations between vitamin D and autoimmune diseases: Mendelian randomization analysis. Seminars in arthritis and rheumatism. 2023. PMID 37437450. DOI: 10.1016/j.semarthrit.2023.152238. Access: abstract_metadata. Study: PMID37437450.

34. Bock G, Prietl B, Mader JK et al. The effect of vitamin D supplementation on peripheral regulatory T cells and β cell function in healthy humans: a randomized controlled trial. Diabetes/metabolism research and reviews. 2011. PMID 22069289. DOI: 10.1002/dmrr.1276. Access: abstract_metadata. Study: PMID22069289.

35. Jorde R, Sneve M, Torjesen PA et al. No effect of supplementation with cholecalciferol on cytokines and markers of inflammation in overweight and obese subjects. Cytokine. 2010. PMID 20122848. DOI: 10.1016/j.cyto.2009.12.006. Access: abstract_metadata. Study: PMID20122848.

36. Tamara L, Kartasasmita CB, Alam A et al. Effects of Vitamin D supplementation on resolution of fever and cough in children with pulmonary tuberculosis: A randomized double-blind controlled trial in Indonesia. Journal of global health. 2022. PMID 35198149. DOI: 10.7189/jogh.12.04015. Access: abstract_metadata. Study: NCT05073965.

37. Annweiler C, Beaudenon M, Gautier J et al. High-dose versus standard-dose vitamin D supplementation in older adults with COVID-19 (COVIT-TRIAL): A multicenter, open-label, randomized controlled superiority trial. PLoS medicine. 2022. PMID 35639792. DOI: 10.1371/journal.pmed.1003999. Access: abstract_metadata. Study: NCT04344041.

38. Atieh O, Daher J, Durieux JC et al. Vitamins K2 and D3 Improve Long COVID, Fungal Translocation, and Inflammation: Randomized Controlled Trial. Nutrients. 2025. PMID 39861434. DOI: 10.3390/nu17020304. Access: abstract_metadata. Study: PMID39861434.

39. Ganmaa D, Uyanga B, Zhou X et al. Vitamin D Supplements for Prevention of Tuberculosis Infection and Disease. The New England journal of medicine. 2020. PMID 32706534. DOI: 10.1056/NEJMoa1915176. Access: full_text_partial. Study: NCT02276755.

40. Camargo CA, Schaumberg DA, Friedenberg G et al. Effect of Daily Vitamin D Supplementation on Risk of Upper Respiratory Infection in Older Adults: A Randomized Controlled Trial. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2024. PMID 38113446. DOI: 10.1093/cid/ciad770. Access: abstract_metadata. Study: VITAL.

41. Angelidi AM, Belanger MJ, Lorinsky MK et al. Vitamin D Status Is Associated With In-Hospital Mortality and Mechanical Ventilation: A Cohort of COVID-19 Hospitalized Patients. Mayo Clinic proceedings. 2021. PMID 33714594. DOI: 10.1016/j.mayocp.2021.01.001. Access: abstract_metadata. Study: PMID33714594.

42. Dimitrakopoulou VI, Tsilidis KK, Haycock PC et al. Circulating vitamin D concentration and risk of seven cancers: Mendelian randomisation study. BMJ (Clinical research ed.). 2017. PMID 29089348. DOI: 10.1136/bmj.j4761. Access: abstract_metadata. Study: PMID29089348.

43. Zhuang Z, Yu C, Guo Y et al. Metabolic Signatures of Genetically Elevated Vitamin D Among Chinese: Observational and Mendelian Randomization Study. The Journal of clinical endocrinology and metabolism. 2021. PMID 33596318. DOI: 10.1210/clinem/dgab097. Access: abstract_metadata. Study: PMID33596318.

44. Afzal S, Brøndum-Jacobsen P, Bojesen SE et al. Genetically low vitamin D concentrations and increased mortality: Mendelian randomisation analysis in three large cohorts. BMJ (Clinical research ed.). 2014. PMID 25406188. DOI: 10.1136/bmj.g6330. Access: abstract_metadata. Study: PMID25406188.

45. Jiang X, Dimou NL, Al-Dabhani K et al. Circulating vitamin D concentrations and risk of breast and prostate cancer: a Mendelian randomization study. International journal of epidemiology. 2019. PMID 30597039. DOI: 10.1093/ije/dyy284. Access: abstract_metadata. Study: PMID30597039.

46. Ye Y, Yang H, Wang Y et al. A comprehensive genetic and epidemiological association analysis of vitamin D with common diseases/traits in the UK Biobank. Genetic epidemiology. 2021. PMID 32918767. DOI: 10.1002/gepi.22357. Access: abstract_metadata. Study: PMID32918767.

47. Chandler PD, Tobias DK, Wang L et al. Association between Vitamin D Genetic Risk Score and Cancer Risk in a Large Cohort of U.S. Women. Nutrients. 2018. PMID 29315215. DOI: 10.3390/nu10010055. Access: abstract_metadata. Study: PMID29315215.

48. Sutherland JP, Zhou A, Hyppönen E. Vitamin D Deficiency Increases Mortality Risk in the UK Biobank : A Nonlinear Mendelian Randomization Study. Annals of internal medicine. 2022. PMID 36279545. DOI: 10.7326/M21-3324. Access: abstract_metadata. Study: PMID36279545.

49. Jiang X, Ge T, Chen CY. The causal role of circulating vitamin D concentrations in human complex traits and diseases: a large-scale Mendelian randomization study. Scientific reports. 2021. PMID 33420236. DOI: 10.1038/s41598-020-80655-w. Access: abstract_metadata. Study: PMID33420236.

50. Scragg R, Stewart AW, Waayer D et al. Effect of Monthly High-Dose Vitamin D Supplementation on Cardiovascular Disease in the Vitamin D Assessment Study : A Randomized Clinical Trial. JAMA cardiology. 2017. PMID 28384800. DOI: 10.1001/jamacardio.2017.0175. Access: abstract_metadata. Study: PMID28384800.

Source-specific evidence cards

[1] Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease.

Shows: VITAL did not significantly reduce its primary invasive-cancer or major-cardiovascular endpoints with vitamin D.

Does not show: This constrains broad prevention in the enrolled population, not every severely deficient or disease-specific subgroup.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 1:RESULTS:paragraph2, 1:RESULTS:paragraph5. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

[2] Effect of Long-term Vitamin D3 Supplementation vs Placebo on Risk of Depression or Clinically Relevant Depressive Symptoms and on Change in Mood Scores: A Randomized Clinical Trial.

Shows: VITAL-DEP did not significantly prevent depression outcomes.

Does not show: This is not a trial of treating every existing depressive disorder or severe deficiency.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

[3] Effect of Vitamin D3 and Omega-3 Fatty Acid Supplementation on Risk of Frailty: An Ancillary Study of a Randomized Clinical Trial.

Shows: VITAL frailty analyses found no clear preventive benefit.

Does not show: Frailty analysis does not establish all possible skeletal or functional effects.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

[4] Effects of Vitamin D3 and Marine Omega-3 Fatty Acids Supplementation on Indicated and Selective Prevention of Depression in Older Adults: Results From the Clinical Center Sub-Cohort of the VITamin D and OmegA-3 TriaL (VITAL).

Shows: A smaller VITAL subgroup did not demonstrate depression prevention.

Does not show: Limited subgroup power and shared parent cohort do not create independent replication.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

[5] Effects of Vitamin D3 Supplementation on Cardiovascular and Cancer Outcomes by eGFR in VITAL.

Shows: VITAL kidney strata showed biochemical vitamin-D/PTH effects without differential cancer/CV benefit.

Does not show: Biochemical target response is not broad disease-incidence reduction.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

[6] Vitamin D supplementation and major cardiovascular events: D-Health randomised controlled trial.

Shows: D-Health cardiovascular analyses suggested a modest signal with an overall confidence interval including no effect.

Does not show: Nominal secondary/subgroup findings are not definitive broad cardiovascular prevention.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

[7] Vitamin D supplementation and cognition-Results from analyses of the D-Health trial.

Shows: D-Health cognitive analyses found no benefit on tested cognition.

Does not show: Same parent trial, selected measures and enrollment restrict scope.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

[8] Effect of vitamin D supplementation on antibiotic use: a randomized controlled trial.

Shows: Pilot supplementation did not clearly reduce overall antibiotic use.

Does not show: An exploratory older subgroup and nonsignificant interaction cannot establish a reliable subgroup effect.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

[9] The Effect of Vitamin D Supplementation on Hypothyroidism in the Randomized Controlled D-Health Trial.

Shows: D-Health tertiary analyses did not reduce incident hypothyroidism.

Does not show: A tertiary endpoint is not independent confirmation of autoimmune prevention.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

[10] The effect of vitamin D supplementation on cancer incidence in the randomised controlled D-Health Trial: Implications for policy and practice.

Shows: D-Health did not reduce overall cancer incidence.

Does not show: Not all cancer subtypes or severely deficient populations are separately resolved.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

[11] Recruitment and results of a pilot trial of vitamin D supplementation in the general population of Australia.

Shows: A pilot showed feasible supplementation and increased vitamin-D levels.

Does not show: Feasibility and biochemical correction are not clinical prevention.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

[12] The D-Health Trial: a randomised controlled trial of the effect of vitamin D on mortality.

Shows: D-Health did not reduce all-cause mortality.

Does not show: Exploratory cancer-mortality analyses do not establish generalized harm; an erratum is attached.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. ErratumIn: PMID35325597. Subclaims: SC1, SC2, SC3.

[13] The effect of vitamin D supplementation on acute respiratory tract infection in older Australian adults: an analysis of data from the D-Health Trial.

Shows: D-Health did not reduce acute respiratory infection incidence, with limited duration findings.

Does not show: Episode duration is distinct from prevention incidence and from severe-deficiency effects.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

[14] Effect of vitamin D supplementation on selected inflammatory biomarkers in older adults: a secondary analysis of data from a randomised, placebo-controlled trial.

Shows: Pilot D-Health work found no clear broad inflammatory-marker improvement.

Does not show: A biomarker null does not establish every clinical outcome.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

[15] Effects of Vitamin D Supplementation on Telomere Length: An Analysis of Data from the Randomised Controlled D-Health Trial.

Shows: D-Health did not change the tested telomere-length endpoint.

Does not show: Telomere length is not a validated substitute for organismal aging or disease prevention.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

[16] Vitamin D Supplementation and Prevention of Type 2 Diabetes.

Shows: D2d's primary diabetes endpoint favored supplementation numerically but did not reach statistical significance.

Does not show: Participants were not selected for vitamin-D deficiency; the result does not prove benefit or exclude a modest effect.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

[17] Effects of Vitamin D Supplementation on Insulin Sensitivity and Secretion in Prediabetes.

Shows: D2d beta-cell measures were null overall with a low-baseline-D subgroup signal.

Does not show: Biomarker subgroup results require replication and cannot establish broad diabetes prevention.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

[18] Vitamin D Supplementation for Prevention of Cancer: The D2d Cancer Outcomes (D2dCA) Ancillary Study.

Shows: D2d did not clearly reduce cancer/polyps in its secondary analysis.

Does not show: Shared cohort and limited event counts restrict precision.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

[19] Vitamin D Receptor Polymorphisms and the Effect of Vitamin D Supplementation on Diabetes Risk Among Adults With Prediabetes.

Shows: D2d genotype analyses suggested differential diabetes response.

Does not show: Baseline genotype is prespecifiable but exploratory interaction requires independent replication.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

[20] Effect of Vitamin D Supplementation on Kidney Function in Adults with Prediabetes: A Secondary Analysis of a Randomized Trial.

Shows: D2d kidney outcomes showed no clear benefit.

Does not show: Secondary renal endpoints do not establish universal absence of vitamin-D effects.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

[21] Effect of intratrial mean 25(OH)D concentration on diabetes risk, by race and weight: an ancillary analysis in the D2d study.

Shows: Higher achieved vitamin-D levels in D2d associated with lower diabetes risk.

Does not show: Conditioning on postrandomization levels does not retain randomized assignment of those levels.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

[22] The effect of vitamin D supplementation on cardiovascular risk in patients with prediabetes: A secondary analysis of the D2d study.

Shows: D2d cardiovascular events were not clearly reduced despite selected risk-score changes.

Does not show: Surrogate change and limited events do not establish clinical prevention.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

[23] Safety and tolerability of high-dose daily vitamin D3 supplementation in the vitamin D and type 2 diabetes (D2d) study-a randomized trial in persons with prediabetes.

Shows: D2d monitored supplementation without a clear major safety difference.

Does not show: Safety under trial monitoring is not proof of efficacy or universal safety; an erratum is attached.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. ErratumIn: PMID35418608. Subclaims: SC1, SC2, SC3.

[24] Vitamin D and marine omega 3 fatty acid supplementation and incident autoimmune disease: VITAL randomized controlled trial.

Shows: The original VITAL autoimmune report found a statistically significant reduction in confirmed incident autoimmune disease.

Does not show: The same cohort's later case confirmation attenuated the estimate; it is not an independently replicated broad signal.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

[25] Vitamin D and Marine n-3 Fatty Acids for Autoimmune Disease Prevention: Outcomes Two Years After Completion of a Double-Blind, Placebo-Controlled Trial.

Shows: Updated VITAL cases weakened the randomized vitamin-D autoimmune estimate and follow-up showed no overall sustained vitamin-D difference.

Does not show: Observational post-trial follow-up is not continued randomized supplementation; attenuation does not exclude all disease-specific effects.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 2:RESULTS:paragraph4. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

[26] Randomized phase I trial of antigen-specific tolerizing immunotherapy with peptide/calcitriol liposomes in ACPA+ rheumatoid arthritis.

Shows: DEN-181 altered immune measures in a small rheumatoid-arthritis phase 1 trial.

Does not show: A peptide/calcitriol combination is not oral vitamin-D population prevention or isolated vitamin-D efficacy.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

[27] Association of vitamin D receptor gene 3'-variants with Hashimoto's thyroiditis in the Croatian population.

Shows: Vitamin-D receptor variants associated with Hashimoto thyroiditis.

Does not show: Association is not a validated exposure instrument or randomized supplementation effect.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

[28] Adding vitamin D3 to the dipeptidyl peptidase-4 inhibitor saxagliptin has the potential to protect β-cell function in LADA patients: A 1-year pilot study.

Shows: LADA combination-treatment arms had selected within-group beta-cell findings.

Does not show: No significant between-group difference on the listed measures; saxagliptin prevents isolating vitamin D.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

[29] Vitamin D Status and Thyroid Autoantibodies in Autoimmune Thyroiditis.

Shows: A retrospective Hashimoto study associated supplementation/level changes with antibody trajectories.

Does not show: Nonrandomized groups and antibody surrogates do not establish clinical prevention.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

[30] Combination therapy with saxagliptin and vitamin D for the preservation of β-cell function in adult-onset type 1 diabetes: a multi-center, randomized, controlled trial.

Shows: A saxagliptin/vitamin-D type 1 diabetes trial missed its primary fasting C-peptide endpoint with a secondary signal.

Does not show: Combination attribution and secondary analysis cannot establish vitamin-D-alone prevention.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

[31] Vitamin D deficiency is associated with thyroid autoimmunity: results from an epidemiological survey in Tianjin, China.

Shows: Low vitamin D associated with thyroid autoantibodies.

Does not show: Reverse causation and common causes remain; antibody presence is not disease-incidence reduction.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

[32] Low Vitamin D Levels Predict Mortality in Ankylosing Spondylitis Patients: A Nationwide Population-Based Cohort Study.

Shows: Low vitamin D associated with mortality in ankylosing spondylitis.

Does not show: Disease-related confounding and subgroup context preclude a supplementation causal claim.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

[33] Associations between vitamin D and autoimmune diseases: Mendelian randomization analysis.

Shows: Mendelian randomization supported a disease-specific psoriasis signal and weaker lupus findings.

Does not show: Instrument assumptions and disease heterogeneity do not establish broad autoimmune prevention.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

[34] The effect of vitamin D supplementation on peripheral regulatory T cells and β cell function in healthy humans: a randomized controlled trial.

Shows: Supplementation increased a T-regulatory-cell measure in a controlled study.

Does not show: Immune-cell percentage change did not demonstrate beta-cell function or disease-incidence benefit.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

[35] No effect of supplementation with cholecalciferol on cytokines and markers of inflammation in overweight and obese subjects.

Shows: Supplementation in obesity did not change the tested cytokine markers.

Does not show: A selected cytokine null does not exclude all vitamin-D pathways.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

[36] Effects of Vitamin D supplementation on resolution of fever and cough in children with pulmonary tuberculosis: A randomized double-blind controlled trial in Indonesia.

Shows: Adjunct vitamin D improved selected symptom-resolution outcomes in children treated for tuberculosis.

Does not show: Treatment response is not prevention of tuberculosis infection or broad disease incidence.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

[37] High-dose versus standard-dose vitamin D supplementation in older adults with COVID-19 (COVIT-TRIAL): A multicenter, open-label, randomized controlled superiority trial.

Shows: COVIT reported an early adjusted mortality signal in older patients treated for acute COVID-19.

Does not show: Open-label acute treatment, short-term endpoint and adjustment do not establish prevention or a durable universal effect.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

[38] Vitamins K2 and D3 Improve Long COVID, Fungal Translocation, and Inflammation: Randomized Controlled Trial.

Shows: A vitamin-K2/D3 Long-COVID combination reported clinical-index improvement.

Does not show: Combination and comparator conditions do not isolate vitamin D or test disease prevention.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

[39] Vitamin D Supplements for Prevention of Tuberculosis Infection and Disease.

Shows: Supplementation raised vitamin-D levels but did not prevent tuberculosis infection or disease in a largely deficient child population.

Does not show: Specific population and outcome; null disease incidence is not proof of every vitamin-D mechanism's absence.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 1:Results:paragraph2, 1:Results:paragraph4. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

[40] Effect of Daily Vitamin D Supplementation on Risk of Upper Respiratory Infection in Older Adults: A Randomized Controlled Trial.

Shows: VITAL found no overall reduction in upper-respiratory infection.

Does not show: The very-low-baseline subgroup was small and uncertain, so not all severe-deficiency effects are resolved.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

[41] Vitamin D Status Is Associated With In-Hospital Mortality and Mechanical Ventilation: A Cohort of COVID-19 Hospitalized Patients.

Shows: Hospital COVID-19 vitamin-D measurements associated with mortality.

Does not show: Acute illness can change measured levels; association does not establish correction benefit.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

[42] Circulating vitamin D concentration and risk of seven cancers: Mendelian randomisation study.

Shows: Mendelian randomization did not support moderate causal effects across seven cancers.

Does not show: Instrument validity and power for small or nonlinear effects remain limitations.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

[43] Metabolic Signatures of Genetically Elevated Vitamin D Among Chinese: Observational and Mendelian Randomization Study.

Shows: Lipid Mendelian randomization lacked strong multiple-testing-corrected findings.

Does not show: Nominal lipid signals are neither robust causal evidence nor hard clinical outcomes.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

[44] Genetically low vitamin D concentrations and increased mortality: Mendelian randomisation analysis in three large cohorts.

Shows: Genetic analysis supported selected mortality associations, differing by cause.

Does not show: Pleiotropy and instrument assumptions remain; genetic lifelong exposure is not an oral supplement trial.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

[45] Circulating vitamin D concentrations and risk of breast and prostate cancer: a Mendelian randomization study.

Shows: Large Mendelian randomization found no convincing breast/prostate cancer effect.

Does not show: Does not exclude all small, nonlinear or population-specific effects.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

[46] A comprehensive genetic and epidemiological association analysis of vitamin D with common diseases/traits in the UK Biobank.

Shows: A phenome-wide genetic study supported selected disease-specific possibilities including multiple sclerosis.

Does not show: Multiple comparisons and instruments do not establish that all low-D associations are causal.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

[47] Association between Vitamin D Genetic Risk Score and Cancer Risk in a Large Cohort of U.S. Women.

Shows: A genetic vitamin-D score did not predict the tested cancers in the women's cohort.

Does not show: Population and instrument limitations constrain small/nonlinear effects.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

[48] Vitamin D Deficiency Increases Mortality Risk in the UK Biobank : A Nonlinear Mendelian Randomization Study.

Shows: Nonlinear Mendelian randomization suggested a low-level mortality relationship.

Does not show: Stratification/instrument assumptions require caution; this is not randomized correction of severe deficiency.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

[49] The causal role of circulating vitamin D concentrations in human complex traits and diseases: a large-scale Mendelian randomization study.

Shows: Multi-trait Mendelian randomization supported selected outcomes, including multiple sclerosis, while most traits were null.

Does not show: A selective genetic association pattern does not prove broad supplement-preventable disease.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

[50] Effect of Monthly High-Dose Vitamin D Supplementation on Cardiovascular Disease in the Vitamin D Assessment Study : A Randomized Clinical Trial.

Shows: ViDA did not reduce cardiovascular events with its tested supplementation regimen.

Does not show: Regimen and population context matter; no inference to all possible dosing or severe deficiency.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

Documentary record

Every grade on this site is reproducible from its record. The files below are the posted edition exactly as assessed.

• ADVERSARIAL_REVIEW.md
• SHA256.txt
• adversarial-findings.json
• codex-correction-provenance.json
• consensus-addendum.md
• consensus-validation.json
• edition-approval-audit.json
• reader-summary.json
• validation-report.json
• validation-round2-2026-10-14.json
• validation.txt
• vitamin-d-deficiency.review.md
• vitamin-d-deficiency.scorecard.json

Sources: 50 · load-bearing claims: 54 · verified: 54 · unverified: 0 · contradicted: 0 · schema 5.3